Figure 1 Study flowchart and patient flow

Slides:



Advertisements
Similar presentations
Figure 1 Alcohol consumption. A
Advertisements

Table 1 Patient characteristics of attendees of the influenza vaccination, irrespective of AF status From: Yield of screening for atrial fibrillation in.
Fig 1 The CONSORT participant flow diagram for primary endpoints.
Figure 1 Study flow chart.
From: Learning by Working in Big Cities
Fig. 1 Nodes in a conceptual knowledge graph
Figure 1: Pneumomediastinum and subcutaneous emphysema as indicated by the arrows. From: Pneumomediastinum and subcutaneous emphysema after successful.
From: Detection of Bacteriuria by Canine Olfaction
Figure 1. The flow chart illustrates the construction process of anti-CRISPRdb, and the information that users can obtain from anti-CRISPRdb. From: Anti-CRISPRdb:
Abstract From: Lung transplantation after ex vivo lung perfusion in two Scandinavian centres Eur J Cardiothorac Surg. Published online October 29, 2018.
Figure 1: Necrobiosis lipoidica: Yellow-brown skin lesions with indurated borders located on both lower legs. Figure 1: Necrobiosis lipoidica: Yellow-brown.
ADAb: anti-drug antibody.
Figure 1 Rates of complications and mortality during index admission for atrial fibrillation ablation for the overall ... Figure 1 Rates of complications.
FIGURE 1 Kidney biopsies of Patients 1 and 2
Figure 1 Hazard ratios as a function of annual mean PM2
Figure 1 Study flow diagram and definition of clinical response
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Figure 1: Axial T2 W images of penis showed a well-defined septated area of 2 cm in the posterior aspect of ... Figure 1: Axial T2 W images.
FIGURE 1 Histological diagnoses divided into 8-year time frames (n = 1208). Unless provided in the caption above, the following copyright applies to the.
FIGURE 1 The effect of daprodustat on hemoglobin (Hgb) levels
Figure 1 Unadjusted Kaplan–Meier curves for all-cause mortality in the transcatheter mitral valve repair and ... Figure 1 Unadjusted Kaplan–Meier curves.
Figure 1 Mechanism of mortality benefit associated with radial access
FIGURE 2 Responses to the question: regarding vasoactive drugs, does your centre use the following frequently, rarely ... FIGURE 2 Responses to the question:
FIGURE 1 Maternal (A) urinary aldosterone; (B) plasma active renin; (C) urinary AGT concentrations; and (D) plasma AGT ... FIGURE 1 Maternal (A) urinary.
FIGURE 1 Flow chart of patient enrollment and exclusion
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Fig. 1 Kaplan-Meier plot of cumulative incidence of cancer onset following dermatomyositis diagnosis stratified ... Anti-TIF1-Ab: anti-transcriptional.
Figure 1 A dot plot illustrating the correlation between the yearly absolute risk difference for both MACE and major ... Figure 1 A dot plot illustrating.
Figure 1 The occurrence of maternal cardiovascular events for the different diagnosis groups. AOP, aortic pathology; ... Figure 1 The occurrence of maternal.
Figure 1 Flortaucipir PET MUBADA/PERSI SUVr at baseline, 9 and 18 months for individual subjects. Each subject is ... Figure 1 Flortaucipir PET MUBADA/PERSI.
Fig. 1 Mean change from baseline in ANC ± s. e
Point estimates with ... Point estimates with 95% CI. HR: hip replacement; KR: knee replacement. Unless provided in the caption above, the following copyright.
Take home figure The protective role of CNP/NPR-B/NPRC.
Figure 1. (A) Ab+ patients showed significantly more often a cognitive impairment compared with ab− patients [57.1% ... Figure 1. (A) Ab+ patients showed.
FIGURE 1 Participant flow diagram. Exercise Counseling Clinic (ECC).
Graph 1. The number of homicide cases per year discussing neuro-evidence. Unless provided in the caption above, the following copyright applies to the.
Figure 1. Analysis of human TRIM5α protein with Blast-Search and PhyML+SMS ‘One click’ workflow. (A) NGPhylogeny.fr ... Figure 1. Analysis of human TRIM5α.
Figure 2. Natural history of chlamydia transmission, with arrows showing the transitions between health states. Figure 2. Natural history of chlamydia.
Figure 1 Nelson-Aalen estimates of the cumulative incidence rates for patients on versus off IST. ON = optic neuritis; ... Figure 1 Nelson-Aalen estimates.
FIGURE 1 Malta: a plate-style food guide
Figure 1. A, Crude incidence rates per 100 person-years of follow-up and 95% confidence intervals for each solid organ ... Figure 1. A, Crude incidence.
FIGURE 1 Study consort diagram
Fig. 2 Case 2. Levels of serum creatinine and anti-GBM antibodies before and during treatment with cyclophosphamide, ... Fig. 2 Case 2. Levels of serum.
Figure 1 Cumulative late adjusted survival in cardiac resynchronization therapy defibrillator and pacemaker patients. ... Figure 1 Cumulative late adjusted.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.
Figure 1. Illustration of DGR systems and their prediction using myDGR
FIGURE 1 Food groups consumed (mean, g/d) among US infants and young children by age group and tertile of mean ... FIGURE 1 Food groups consumed (mean,
Figure 1. Schematic diagram of solar energy and coal-fired power generation system. Unless provided in the caption above, the following copyright applies.
Figure 1. Uncertainty reduction, value creation, and appropriation in two case studies. Unless provided in the caption above, the following copyright applies.
Figure 1 Ratio of the geometric mean concentration of hsTnT (A) and sST2 (B) at baseline (BL) and each subsequent ... Figure 1 Ratio of the geometric mean.
Figure 1. Time to clinical stability (a) and time to defervescence (b) in patients with pneumococcal pneumonia. ... Figure 1. Time to clinical stability.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Figure 1. MERMAID web server interface (Start page, Parameter page): MERMAID provides two ways to submit a protein ... Figure 1. MERMAID web server interface.
Figure 1. Yvis platform overview
Figure 1. The framework of NetGO with seven steps
Figure 1 Patient disposition
Figure 1 Diagram of patient and procedural follow-up for Cohorts A, B, and C. Cohort A: 6-month OCT and 12-month OCT, ... Figure 1 Diagram of patient and.
Figure 1. Trial profile. (A) Part A and (B) part B
Figure 1 Design of trials included in individual patient data meta-analysis. Unless provided in the caption above, the following copyright applies to the.
Figure 1 Distribution of WCD use days in WEARIT-II
Figure 1. The proportion of CSBM responders over the 2-week treatment period (A), the proportion of SBM responders by ... Figure 1. The proportion of CSBM.
Figure 1 Genetic results. No case had more than one diagnostic result
Figure 1 Grant agencies and charitable foundations supporting Plan S.
Figure 1. (A) Baseline contrast-enhanced CT scan of melanoma patient presenting with metastases in the liver and lymph ... Figure 1. (A) Baseline contrast-enhanced.
Figure 1. Prevalence of parasitic infection and anemia among the children. Unless provided in the caption above, the following copyright applies to the.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.
Source:Zimnisky (2014). Source:Zimnisky (2014).
Figure 1 Mechanisms of mitral regurgitation.
Figure 1 ABCDE of primary prevention.2
Figure 1. Hepatitis C screening and diagnostic algorithm at the MSF clinic, Karachi, Pakistan, March 2016–September ... Figure 1. Hepatitis C screening.
Presentation transcript:

Figure 1 Study flowchart and patient flow Figure 1 Study flowchart and patient flow. MAE, major arrhythmic event; NIRF, non-invasive risk factors; PEP, primary ... Figure 1 Study flowchart and patient flow. MAE, major arrhythmic event; NIRF, non-invasive risk factors; PEP, primary endpoint (MAE occurrence); PVS, programmed ventricular stimulation—see ‘Methods’ section for more details. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) 2019. Published by Oxford University Press on behalf of the European Society of Cardiology.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com Eur Heart J, ehz260, https://doi.org/10.1093/eurheartj/ehz260 The content of this slide may be subject to copyright: please see the slide notes for details.

Figure 2 Kaplan–Meier survival curves by risk group Figure 2 Kaplan–Meier survival curves by risk group. No primary endpoint events occurred in Groups 1 and 2. Patients ... Figure 2 Kaplan–Meier survival curves by risk group. No primary endpoint events occurred in Groups 1 and 2. Patients declining programmed ventricular stimulation are not depicted (unknown risk group). NIRF, non-invasive risk factor. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) 2019. Published by Oxford University Press on behalf of the European Society of Cardiology.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com Eur Heart J, ehz260, https://doi.org/10.1093/eurheartj/ehz260 The content of this slide may be subject to copyright: please see the slide notes for details.

Take home figure Outline of study design and findings Take home figure Outline of study design and findings. Starting with a cohort exhibiting a prevalence of major arrhythmic ... Take home figure Outline of study design and findings. Starting with a cohort exhibiting a prevalence of major arrhythmic events at the 1.5% level (after a 32-month follow-up), the two-step, programmed ventricular stimulation-inclusive approach allowed for the identification of a high arrhythmic risk subgroup with a major arrhythmic event prevalence reaching 22% (almost 15-fold higher than baseline). LP, late potentials; MAE, major arrhythmic event; NIRF, non-invasive risk factors; nsVT, non-sustained ventricular tachycardia; PVC, premature ventricular complex. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) 2019. Published by Oxford University Press on behalf of the European Society of Cardiology.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com Eur Heart J, ehz260, https://doi.org/10.1093/eurheartj/ehz260 The content of this slide may be subject to copyright: please see the slide notes for details.